Cizzle Biotechnology AZD 1656 deal means near term revenue streams (Interview)

Cizzle Biotechnology Holdings plc (LON:CIZ) Executive Chairman Allan Syms joins DirectorsTalk Interviews to discuss an agreement with Conduit Pharmaceuticals and St George Street Capital to acquire a 5% economic interest in the commercialisation of the AZD 1656 asset.

Allan tells us more about the deal and how it fits with Cizzle’s previous agreement on AZD 1656, the history of the asset and what its looking to treat, who the partners Conduit Pharmaceuticals and St George Street Capital are and how this agreement will work from a financial point of view.

Cizzle Biotechnology is a UK based developer of a blood test for the early detection of a majority of different forms of lung cancer.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Cizzle Biotech

    More articles like this

    Cizzle Biotech

    Cizzle Biotechnology completes evaluation programme with Bio-Techne

    Bio-Techne Corporation (NASDAQ: TECH) and Cizzle Biotechnology Holdings plc (LON:CIZ), the UK-based diagnostics developer, have announced recent progress evaluating specific monoclonal antibodies for Cizzle’s CIZ1B cancer biomarker. Cizzle has successfully completed an evaluation programme aimed at assessing the feasibility of

    Cizzle Biotech

    Cizzle Biotechnology secures transaction with Conduit

    Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced that it has agreed a put option to sell: (i) its 5% economic interest in the commercialisation of the AZD 1656 asset to treat

    Cizzle Biotech

    Cizzle Biotechnology AGM to be held on 27 June 2022

    Cizzle Biotechnology plc (LON:CIZ), the UK-based diagnostics developer, has announced that copies of the annual report and accounts for the year ended 31 December 2021, together with the notice of Annual General Meeting, have been sent to